Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice

Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether giving pregnant women a specific probiotic supplement can help reduce the risk of neonatal jaundice in their newborns. Neonatal jaundice is a common condition in newborns that causes yellowing of the skin and eyes due to high bilirubin levels. The trial involves 94 pregnant women, split into two groups: one will receive the probiotic supplement called Vivomixx®, and the other will receive a placebo (a non-active treatment). The researchers will look at how this supplementation affects not only the babies’ jaundice but also the bacteria in breast milk and the gut of both mothers and infants.

To participate in this study, women need to be between 18 and 45 years old, be pregnant with a single baby, and be at 28 to 34 weeks of pregnancy. Some factors, like certain health conditions or medications, might make someone ineligible. If you join the trial, you'll be randomly assigned to either the probiotic or placebo group, and you'll be monitored throughout the study. This research is taking place at Prince of Wales Hospital, and it aims to provide valuable insights into how probiotics can improve the health of newborns.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • All pregnant women aged 18-45 years old.
• • Gestational age of 28-34 weeks
• • Normal singleton pregnancy
• Exclusion Criteria:
• • Foetal abnormality
• • Mothers with antibiotic medication during the allocation
• • Couples with glucose 6-phosphate dehydrogenase enzyme deficiency
• • Couples with known rhesus or haemolytic disease history
• • Plan of place of birth at other hospitals other than Prince of Wales Hospital
• • known breast disorder or any contraindication for breastfeeding.